KR20160003228A - 3-(5-아미노-2-메틸-4-옥소퀴나졸린-3(4ｈ)-일)피페리딘-2,6-디온의 합성 - Google Patents
3-(5-아미노-2-메틸-4-옥소퀴나졸린-3(4ｈ)-일)피페리딘-2,6-디온의 합성 Download PDFInfo
- Publication number
- KR20160003228A KR20160003228A KR1020157034184A KR20157034184A KR20160003228A KR 20160003228 A KR20160003228 A KR 20160003228A KR 1020157034184 A KR1020157034184 A KR 1020157034184A KR 20157034184 A KR20157034184 A KR 20157034184A KR 20160003228 A KR20160003228 A KR 20160003228A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- dione
- nitro
- oxoquinazolin
- certain embodiments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818254P | 2013-05-01 | 2013-05-01 | |
| US61/818,254 | 2013-05-01 | ||
| PCT/US2014/036083 WO2014179416A1 (en) | 2013-05-01 | 2014-04-30 | Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160003228A true KR20160003228A (ko) | 2016-01-08 |
Family
ID=50885008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157034184A Withdrawn KR20160003228A (ko) | 2013-05-01 | 2014-04-30 | 3-(5-아미노-2-메틸-4-옥소퀴나졸린-3(4ｈ)-일)피페리딘-2,6-디온의 합성 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US9067912B2 (https=) |
| EP (2) | EP3199532A1 (https=) |
| JP (2) | JP6490055B2 (https=) |
| KR (1) | KR20160003228A (https=) |
| CN (2) | CN107935994A (https=) |
| AR (1) | AR096165A1 (https=) |
| AU (2) | AU2014260011A1 (https=) |
| CA (1) | CA2910971A1 (https=) |
| CY (1) | CY1119525T1 (https=) |
| DK (1) | DK2991976T3 (https=) |
| ES (1) | ES2645944T3 (https=) |
| HR (1) | HRP20171535T1 (https=) |
| HU (1) | HUE034770T2 (https=) |
| LT (1) | LT2991976T (https=) |
| MX (1) | MX363652B (https=) |
| NZ (1) | NZ628322A (https=) |
| PH (1) | PH12015502477A1 (https=) |
| PL (1) | PL2991976T3 (https=) |
| PT (1) | PT2991976T (https=) |
| RS (1) | RS56565B1 (https=) |
| RU (1) | RU2015151359A (https=) |
| SG (1) | SG11201508836XA (https=) |
| SI (1) | SI2991976T1 (https=) |
| SM (1) | SMT201700513T1 (https=) |
| TW (1) | TW201536766A (https=) |
| WO (1) | WO2014179416A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2428513T3 (en) | 2006-09-26 | 2017-08-21 | Celgene Corp | 5-substituted quinazolinone derivatives as anti-cancer agents |
| JP5959543B2 (ja) | 2011-03-11 | 2016-08-02 | セルジーン コーポレイション | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンの固体形態、並びにそれらの医薬組成物及び使用 |
| ES2814952T3 (es) | 2012-09-04 | 2021-03-29 | Celgene Corp | Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos |
| EP3316888A1 (en) | 2015-07-02 | 2018-05-09 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
| CN106083622B (zh) * | 2016-06-16 | 2018-06-19 | 常州齐晖药业有限公司 | 一种甲苯咪唑中间体3,4-二氨基二苯甲酮的制备方法 |
| WO2018165142A1 (en) * | 2017-03-07 | 2018-09-13 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
| CN113101295A (zh) * | 2020-03-20 | 2021-07-13 | 上海疆云医疗健康科技有限公司 | 二苯乙烯类似物在治疗糖尿病肾脏疾病中的用途 |
| KR20240055046A (ko) * | 2021-09-02 | 2024-04-26 | 신톤 비.브이. | 오시머티닙을 제조하는 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009539878A (ja) * | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
| DK2428513T3 (en) * | 2006-09-26 | 2017-08-21 | Celgene Corp | 5-substituted quinazolinone derivatives as anti-cancer agents |
| JP5959543B2 (ja) * | 2011-03-11 | 2016-08-02 | セルジーン コーポレイション | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンの固体形態、並びにそれらの医薬組成物及び使用 |
| AU2012229300B2 (en) * | 2011-03-11 | 2017-04-20 | Celgene Corporation | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione |
| ES2814952T3 (es) * | 2012-09-04 | 2021-03-29 | Celgene Corp | Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos |
| CA2935495C (en) * | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
-
2014
- 2014-04-30 SM SM20170513T patent/SMT201700513T1/it unknown
- 2014-04-30 HR HRP20171535TT patent/HRP20171535T1/hr unknown
- 2014-04-30 AR ARP140101806A patent/AR096165A1/es unknown
- 2014-04-30 LT LTEP14728381.6T patent/LT2991976T/lt unknown
- 2014-04-30 AU AU2014260011A patent/AU2014260011A1/en not_active Abandoned
- 2014-04-30 HU HUE14728381A patent/HUE034770T2/hu unknown
- 2014-04-30 EP EP17161076.9A patent/EP3199532A1/en not_active Withdrawn
- 2014-04-30 CA CA2910971A patent/CA2910971A1/en not_active Abandoned
- 2014-04-30 CN CN201810004591.8A patent/CN107935994A/zh active Pending
- 2014-04-30 WO PCT/US2014/036083 patent/WO2014179416A1/en not_active Ceased
- 2014-04-30 ES ES14728381.6T patent/ES2645944T3/es active Active
- 2014-04-30 KR KR1020157034184A patent/KR20160003228A/ko not_active Withdrawn
- 2014-04-30 TW TW103115643A patent/TW201536766A/zh unknown
- 2014-04-30 CN CN201480038438.7A patent/CN105377831B/zh not_active Expired - Fee Related
- 2014-04-30 EP EP14728381.6A patent/EP2991976B1/en active Active
- 2014-04-30 SI SI201430431T patent/SI2991976T1/sl unknown
- 2014-04-30 PT PT147283816T patent/PT2991976T/pt unknown
- 2014-04-30 DK DK14728381.6T patent/DK2991976T3/da active
- 2014-04-30 SG SG11201508836XA patent/SG11201508836XA/en unknown
- 2014-04-30 US US14/266,448 patent/US9067912B2/en not_active Expired - Fee Related
- 2014-04-30 NZ NZ628322A patent/NZ628322A/en not_active IP Right Cessation
- 2014-04-30 RU RU2015151359A patent/RU2015151359A/ru unknown
- 2014-04-30 MX MX2015015073A patent/MX363652B/es unknown
- 2014-04-30 JP JP2016511825A patent/JP6490055B2/ja not_active Expired - Fee Related
- 2014-04-30 PL PL14728381T patent/PL2991976T3/pl unknown
- 2014-04-30 RS RS20171105A patent/RS56565B1/sr unknown
-
2015
- 2015-06-10 US US14/736,146 patent/US9266858B2/en not_active Expired - Fee Related
- 2015-09-24 US US14/864,614 patent/US9303014B2/en not_active Expired - Fee Related
- 2015-10-27 PH PH12015502477A patent/PH12015502477A1/en unknown
-
2017
- 2017-02-13 AU AU2017200965A patent/AU2017200965A1/en not_active Abandoned
- 2017-10-26 CY CY20171101119T patent/CY1119525T1/el unknown
-
2018
- 2018-12-06 JP JP2018229189A patent/JP2019069958A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20160003228A (ko) | 3-(5-아미노-2-메틸-4-옥소퀴나졸린-3(4ｈ)-일)피페리딘-2,6-디온의 합성 | |
| AU2018380426B2 (en) | Processes for making modulators of cystic fibrosis transmembrane conductance regulator | |
| AU2009247262B2 (en) | Amide compound | |
| CN108925135A (zh) | 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法 | |
| EP2707367B1 (en) | Methods for preparing naphthyridines | |
| RS58786B1 (sr) | Novi aminski derivati ili njihove soli kao inhibitori tnf alfa | |
| JP2022521537A (ja) | イミダゾピリジニル化合物及び増殖性障害の処置のためのその使用 | |
| CN117736206A (zh) | 作为mc4r拮抗剂的脲类衍生物、药物组合物及其在医药上的应用 | |
| CN112585126A (zh) | 四环化合物的制备方法 | |
| JP2006083085A (ja) | 二環性ピリミジン誘導体の製造法およびその合成中間体 | |
| TWI762527B (zh) | 色氨酸羥化酶-１抑製劑製備方法 | |
| CN114907315B (zh) | Selitrectinib中间体的合成方法 | |
| CN108191862B (zh) | 4-羟基-2-取代吡唑并吡啶类化合物的合成方法 | |
| WO2026042088A1 (en) | Trycyclic derivatives and their use as complement factor b inhibitors | |
| HK40051429B (zh) | 四环化合物的制备方法 | |
| TW202527947A (zh) | 芳香醯肼類衍生物及其醫藥用途 | |
| HK40058867A (en) | Imidazopyridinyl compounds and use thereof for treatment of proliferative disorders | |
| HK40051429A (en) | Method of producing tetracyclic compound | |
| TW201938547A (zh) | 1,3‐二取代之吡唑化合物之製備方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20151130 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20170913 |
|
| WITB | Written withdrawal of application |